|
Jul 26
|
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
|
|
Jul 24
|
Beam Therapeutics Stock Earns RS Rating Jump To 85
|
|
Jul 24
|
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
|
|
Jul 22
|
3 Gene Editing Stocks Shaping the Future of Medicine
|
|
Jun 14
|
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
|
|
May 14
|
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
|
|
May 13
|
15 Best ARK Stocks To Buy Now
|
|
May 9
|
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
|
|
May 9
|
Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
|
|
May 8
|
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
|
|
May 8
|
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
|
|
May 8
|
Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview
|
|
May 7
|
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
|
|
May 2
|
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 1
|
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 11
|
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
|
|
Mar 28
|
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
|
|
Mar 26
|
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
|
|
Jan 29
|
Why Beam Therapeutics Stock Zoomed 17% Higher Today
|
|
Jan 16
|
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
|